Efficacy and safety of low molecular weight heparin in renal transplantation

Ahmed M. Alkhunaizi, Ali J. Olyaei, John M. Barry, Angelo M DeMattos, Michael J. Conlin, Michael J. Lemmers, William M. Bennett, Douglas J. Norman

Research output: Contribution to journalArticle

33 Citations (Scopus)

Abstract

Background. Deep venous thrombosis (DVT) is a common problem with potentially devastating results in patients undergoing major surgical procedures. Certain renal transplant recipients are particularly at risk for allograft loss as a consequence of renal vein and artery thrombosis. Over the past few years, low molecular weight heparin has been well established as an accepted modality of treatment and prophylaxis of DVT. The efficacy and safety of low molecular weight heparin in the prophylaxis of DVT following renal transplantation in adults has not previously been reported. Methods. Dalteparin was administered to 120 adult renal transplant recipients postoperatively at the Oregon Health Sciences University. Results. No patient developed allograft arterial or venous thrombosis. One patient developed subclavian vein thrombosis. No bleeding complications were encountered, and side effects were very minimal. Conclusion. Prophylaxis with dalteparin is an effective and safe modality for the prevention of thrombosis in adult patients undergoing renal transplantation.

Original languageEnglish (US)
Pages (from-to)533-534
Number of pages2
JournalTransplantation
Volume66
Issue number4
DOIs
StatePublished - Aug 27 1998
Externally publishedYes

Fingerprint

Low Molecular Weight Heparin
Venous Thrombosis
Kidney Transplantation
Dalteparin
Safety
Thrombosis
Allografts
Kidney
Subclavian Vein
Renal Veins
Renal Artery
Hemorrhage
Health
Transplant Recipients
Therapeutics

ASJC Scopus subject areas

  • Transplantation
  • Immunology

Cite this

Alkhunaizi, A. M., Olyaei, A. J., Barry, J. M., DeMattos, A. M., Conlin, M. J., Lemmers, M. J., ... Norman, D. J. (1998). Efficacy and safety of low molecular weight heparin in renal transplantation. Transplantation, 66(4), 533-534. https://doi.org/10.1097/00007890-199808270-00020

Efficacy and safety of low molecular weight heparin in renal transplantation. / Alkhunaizi, Ahmed M.; Olyaei, Ali J.; Barry, John M.; DeMattos, Angelo M; Conlin, Michael J.; Lemmers, Michael J.; Bennett, William M.; Norman, Douglas J.

In: Transplantation, Vol. 66, No. 4, 27.08.1998, p. 533-534.

Research output: Contribution to journalArticle

Alkhunaizi, AM, Olyaei, AJ, Barry, JM, DeMattos, AM, Conlin, MJ, Lemmers, MJ, Bennett, WM & Norman, DJ 1998, 'Efficacy and safety of low molecular weight heparin in renal transplantation', Transplantation, vol. 66, no. 4, pp. 533-534. https://doi.org/10.1097/00007890-199808270-00020
Alkhunaizi, Ahmed M. ; Olyaei, Ali J. ; Barry, John M. ; DeMattos, Angelo M ; Conlin, Michael J. ; Lemmers, Michael J. ; Bennett, William M. ; Norman, Douglas J. / Efficacy and safety of low molecular weight heparin in renal transplantation. In: Transplantation. 1998 ; Vol. 66, No. 4. pp. 533-534.
@article{72e455ff726549569a0b5c8da42a71c1,
title = "Efficacy and safety of low molecular weight heparin in renal transplantation",
abstract = "Background. Deep venous thrombosis (DVT) is a common problem with potentially devastating results in patients undergoing major surgical procedures. Certain renal transplant recipients are particularly at risk for allograft loss as a consequence of renal vein and artery thrombosis. Over the past few years, low molecular weight heparin has been well established as an accepted modality of treatment and prophylaxis of DVT. The efficacy and safety of low molecular weight heparin in the prophylaxis of DVT following renal transplantation in adults has not previously been reported. Methods. Dalteparin was administered to 120 adult renal transplant recipients postoperatively at the Oregon Health Sciences University. Results. No patient developed allograft arterial or venous thrombosis. One patient developed subclavian vein thrombosis. No bleeding complications were encountered, and side effects were very minimal. Conclusion. Prophylaxis with dalteparin is an effective and safe modality for the prevention of thrombosis in adult patients undergoing renal transplantation.",
author = "Alkhunaizi, {Ahmed M.} and Olyaei, {Ali J.} and Barry, {John M.} and DeMattos, {Angelo M} and Conlin, {Michael J.} and Lemmers, {Michael J.} and Bennett, {William M.} and Norman, {Douglas J.}",
year = "1998",
month = "8",
day = "27",
doi = "10.1097/00007890-199808270-00020",
language = "English (US)",
volume = "66",
pages = "533--534",
journal = "Transplantation",
issn = "0041-1337",
publisher = "Lippincott Williams and Wilkins",
number = "4",

}

TY - JOUR

T1 - Efficacy and safety of low molecular weight heparin in renal transplantation

AU - Alkhunaizi, Ahmed M.

AU - Olyaei, Ali J.

AU - Barry, John M.

AU - DeMattos, Angelo M

AU - Conlin, Michael J.

AU - Lemmers, Michael J.

AU - Bennett, William M.

AU - Norman, Douglas J.

PY - 1998/8/27

Y1 - 1998/8/27

N2 - Background. Deep venous thrombosis (DVT) is a common problem with potentially devastating results in patients undergoing major surgical procedures. Certain renal transplant recipients are particularly at risk for allograft loss as a consequence of renal vein and artery thrombosis. Over the past few years, low molecular weight heparin has been well established as an accepted modality of treatment and prophylaxis of DVT. The efficacy and safety of low molecular weight heparin in the prophylaxis of DVT following renal transplantation in adults has not previously been reported. Methods. Dalteparin was administered to 120 adult renal transplant recipients postoperatively at the Oregon Health Sciences University. Results. No patient developed allograft arterial or venous thrombosis. One patient developed subclavian vein thrombosis. No bleeding complications were encountered, and side effects were very minimal. Conclusion. Prophylaxis with dalteparin is an effective and safe modality for the prevention of thrombosis in adult patients undergoing renal transplantation.

AB - Background. Deep venous thrombosis (DVT) is a common problem with potentially devastating results in patients undergoing major surgical procedures. Certain renal transplant recipients are particularly at risk for allograft loss as a consequence of renal vein and artery thrombosis. Over the past few years, low molecular weight heparin has been well established as an accepted modality of treatment and prophylaxis of DVT. The efficacy and safety of low molecular weight heparin in the prophylaxis of DVT following renal transplantation in adults has not previously been reported. Methods. Dalteparin was administered to 120 adult renal transplant recipients postoperatively at the Oregon Health Sciences University. Results. No patient developed allograft arterial or venous thrombosis. One patient developed subclavian vein thrombosis. No bleeding complications were encountered, and side effects were very minimal. Conclusion. Prophylaxis with dalteparin is an effective and safe modality for the prevention of thrombosis in adult patients undergoing renal transplantation.

UR - http://www.scopus.com/inward/record.url?scp=0032572707&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032572707&partnerID=8YFLogxK

U2 - 10.1097/00007890-199808270-00020

DO - 10.1097/00007890-199808270-00020

M3 - Article

C2 - 9734500

AN - SCOPUS:0032572707

VL - 66

SP - 533

EP - 534

JO - Transplantation

JF - Transplantation

SN - 0041-1337

IS - 4

ER -